Mainz Biomed BV (MYNZ)vsThermo Fisher Scientific Inc (TMO)
MYNZ
Mainz Biomed BV
$2.46
+0.41%
HEALTHCARE · Cap: $7.90M
TMO
Thermo Fisher Scientific Inc
$472.80
-2.31%
HEALTHCARE · Cap: $176.04B
Smart Verdict
WallStSmart Research — data-driven comparison
Thermo Fisher Scientific Inc generates 6848553% more annual revenue ($45.20B vs $659,940). TMO leads profitability with a 15.1% profit margin vs 0.0%. TMO earns a higher WallStSmart Score of 62/100 (C+).
MYNZ
Avoid18
out of 100
Grade: F
TMO
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MYNZ.
Margin of Safety
-42.6%
Fair Value
$331.35
Current Price
$472.80
$141.45 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Large-cap with strong market position
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Elevated debt levels
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MYNZ
MYNZ has a balanced fundamental profile.
Bull Case : TMO
The strongest argument for TMO centers on Market Cap. Profitability is solid with margins at 15.1% and operating margin at 17.9%.
Bear Case : MYNZ
The primary concerns for MYNZ are EPS Growth, Market Cap, Profit Margin.
Bear Case : TMO
The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
MYNZ profiles as a value stock while TMO is a mature play — different risk/reward profiles.
TMO carries more volatility with a beta of 0.87 — expect wider price swings.
TMO is growing revenue faster at 6.2% — sustainability is the question.
TMO generates stronger free cash flow (816M), providing more financial flexibility.
Bottom Line
TMO scores higher overall (62/100 vs 18/100), backed by strong 15.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Mainz Biomed BV
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Mainz Biomed BV is an innovative biotechnology company specializing in the development of advanced diagnostic solutions for early cancer detection, with a particular emphasis on gastrointestinal disorders. The company's flagship product, a proprietary non-invasive colorectal cancer screening test, employs state-of-the-art biomarker technology to improve the accuracy and accessibility of screenings. As a key player in the rapidly expanding diagnostics market, Mainz Biomed is dedicated to meeting critical clinical needs and enhancing patient outcomes. With a strong intellectual property position and a focus on research and development, the company is poised to capitalize on the increasing global demand for effective cancer diagnostic tools.
Thermo Fisher Scientific Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?